HIV incidence is the rate at which new HIV infections occur in populations. While HIV prevalence measures overall disease burden, HIV incidence tracks the leading edge of the HIV/AIDS epidemic. Accurate HIV incidence estimates are critical for monitoring the HIV/AIDS epidemic, identifying populations at high risk of HIV acquisition, targeting prevention efforts, and designing and evaluating HIV prevention trials. Current methods for cross-sectional HIV incidence determination are insufficiently accurate. Our goal is to develop and validate accurate, cost-effective methods for cross-sectional HIV incidence determination. Our hypothesis is that diverse laboratory assays and robust statistical modeling can be combined to improve the accuracy of cross-sectional HIV incidence estimates. We will focus on analysis of HIV incidence in both subtype B (the major subtype driving the HIV/AIDS epidemic in the United States) and subtype C (the major subtype driving the HIV/AIDS epidemic in sub-Saharan Africa);other subtypes prevalent in sub-Saharan Africa will also be analyzed.
The Specific Aims of the project are:
Aim 1 : Continue to build a repository of diverse, well-characterized samples with information on the duration of HIV infection. Analyze the samples using serologic HIV incidence assays.
Aim 2 : Further develop and validate a novel high resolution melting (HRM) assay for HIV diversity. Determine whether HIV diversity can be used as a biomarker to differentiate between individuals with recent vs. chronic HIV infection.
Aim 3 : Use statistical analysis and mathematical modeling to assess the accuracy of methods for HIV incidence determination. Apply those approaches to data from Aim 1 (CD4 cell count, HIV viral load, and data from serologic assays) and Aim 2 (data from the HRM assay) to identify methods for HIV incidence determination that perform well in a wide variety of settings, and to assess their relative costs. Our repository will include samples from at least 19 completed clinical trials, cohort studies, and research projects representing key geographic, demographic, and clinically-relevant populations. Over 10,000 of the samples are already in hand. We will integrate laboratory science with statistical analysis and mathematical modeling in all phases of the project, and will evaluate a broad range of design parameters, including use of individual assays versus multi-assay algorithms, use of different assay cutoffs, and sequential ordering of assays. We believe that this comprehensive approach will lead to identification of accurate and cost-effective methods for cross-sectional HIV incidence determination. ) )
This project will evaluate and optimize methods that can be used to determine HIV incidence (the rate of new HIV infections) from cross sectional surveys of single blood samples collected from individuals. These methods are needed to monitor the HIV/AIDS epidemic, to identify populations at high risk of HIV infection, to target HIV prevention efforts, and to design and evaluate HIV prevention trials.
|Eshleman, Susan H; Piwowar-Manning, Estelle; Sivay, Mariya V et al. (2018) Performance of the BioPlex 2200 HIV Ag-Ab assay for identifying acute HIV infection. J Clin Virol 99-100:67-70|
|Laeyendecker, Oliver; Konikoff, Jacob; Morrison, Douglas E et al. (2018) Identification and validation of a multi-assay algorithm for cross-sectional HIV incidence estimation in populations with subtype C infection. J Int AIDS Soc 21:|
|Schlusser, Katherine E; Sharma, Shweta; de la Torre, Pola et al. (2018) Comparison of Self-report to Biomarkers of Recent HIV Infection: Findings from the START Trial. AIDS Behav 22:2277-2283|
|Kirkpatrick, Allison R; Unsal, Aylin B; Blankson, Joel N et al. (2017) Weak HIV Antibody Responses in Perinatally Infected Young Adults: Weak HIV Antibody Responses in Perinatally Infected Adults. Pediatr Infect Dis J 36:1064-1066|
|Fogel, Jessica M; Piwowar-Manning, Estelle; Debevec, Barbara et al. (2017) Brief Report: Impact of Early Antiretroviral Therapy on the Performance of HIV Rapid Tests and HIV Incidence Assays. J Acquir Immune Defic Syndr 75:426-430|
|Kassanjee, Reshma; De Angelis, Daniela; Farah, Marian et al. (2017) Cross-Sectional HIV Incidence Surveillance: A Benchmarking of Approaches for Estimating the 'Mean Duration of Recent Infection'. Stat Commun Infect Dis 9:|
|Schlusser, Katherine E; Pilcher, Christopher; Kallas, Esper G et al. (2017) Comparison of cross-sectional HIV incidence assay results from dried blood spots and plasma. PLoS One 12:e0172283|
|Cepeda, Javier A; Solomon, Sunil S; Srikrishnan, Aylur K et al. (2017) Injection Drug Network Characteristics Are Important Markers of HIV Risk Behavior and Lack of Viral Suppression. J Acquir Immune Defic Syndr 75:257-264|
|Wendel, Sarah K; Longosz, Andrew F; Eshleman, Susan H et al. (2017) Short Communication: The Impact of Viral Suppression and Viral Breakthrough on Limited-Antigen Avidity Assay Results in Individuals with Clade B HIV Infection. AIDS Res Hum Retroviruses 33:325-327|
|Schlusser, Katherine E; Konikoff, Jacob; Kirkpatrick, Allison R et al. (2017) Short Communication: Comparison of Maxim and Sedia Limiting Antigen Assay Performance for Measuring HIV Incidence. AIDS Res Hum Retroviruses 33:555-557|
Showing the most recent 10 out of 52 publications